Feb 13,2023

Digital Diabetes Management Global Market Report 2022: Sector to Reach $29.6 Billion by 2027 at a CAGR of 22.64%

The global digital diabetes management market size reached US$ 8.7 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 29.6 Billion by 2027, exhibiting a CAGR of 22.64% during 2021-2027.

#mobile app

#insulin pen

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Sanofi announces change in R&D leadership

Sanofi announced today that Dr. John Reed, its Global Head of R&D, will be leaving the company. Dr. Dietmar Berger has agreed to take the leadership of the team ad interim. Dr. Berger has been serving as Chief Medical Officer and Global Head of Development since he joined Sanofi in 2019, after an extensive and successful career at various other pharmaceutical companies including Genentech, Bayer and Amgen.

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch

U.S. Centers for Medicare & Medicaid Services has approved coverage for Dexcom G7. Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, Dexcom G7 will be accessible to all Medicare patients with diabetes who meet the eligibility criteria when the system launches this Friday, Feb. 17.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Glucose Biosensors Market to Worth US$ 46.16 Billion by 2033

The global glucose biosensors market is valued at US$ 14.09 billion in 2023 and is predicted to increase rapidly at a CAGR of 12.6% from 2023 to 2033, as per a new market analysis by Fact.MR, a market research and competitive intelligence provider. This high market growth can be attributed to aspects such as the rising prevalence of diabetes and the rapid adoption of improved glucose biosensor devices.

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Global Digital Diabetes Management Market Report 2022 to 2027: Featuring Dexcom, F. Hoffmann-La Roche, Medtronic and Novo Nordisk Among Others

The global digital diabetes management market size reached US$ 8.7 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 29.6 Billion by 2027, exhibiting a CAGR of 22.64% during 2021-2027.

View Analyst & Ambassador Comments
Go to original news
Feb 13,2023

Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies

Insulet Corporation and Bigfoot Biomedical today announced Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies. Insulet paid $25M for the acquisition, which includes certain Bigfoot patents related to pumps that may be used for AID therapy.

COLLABORATION MERGERS & ACQUISITION

#product & service

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 10,2023

Abbott is bullish on FreeStyle Libre growth in 2023

Abbott plans to “go more aggressively” into the continuous glucose monitor (CGM) market with its FreeStyle Libre 3 this year. Chair and CEO Robert Ford said on the company’s most recent earnings call that the company expects growth for the platform this year. FreeStyle Libre 3 received FDA clearance in May 2022. Ford cited full-year growth for the Libre platform of 21% overall. Revenues grew by 42% in the U.S., too. Backorders and supply chain issues hampered growth internationally, he noted, but sales still grew in the mid-teens percentage-wise.

PRODUCT

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Feb 09,2023

Artificial pancreas market size expected to grow at a CAGR of 19.15%

According to Technavio, the global artificial pancreas market size is estimated to grow by USD 450.95 million from 2021 to 2026. The market is estimated to grow at a CAGR of 19.15% during the forecast period. Moreover, the growth momentum will accelerate. North America will account for 43% of the market's growth during the forecast period. The rising global burden of diabetes is driving the market growth. The increase in awareness programs for diabetes is a key trend in the market.

View Analyst & Ambassador Comments
Go to original news
Feb 09,2023

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022. In the fourth quarter of 2022, worldwide revenue grew 17% to $815.2 million, up from $698.2 million in the fourth quarter of 2021. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases. Full year revenue grew 19% versus the prior year to $2.91 billion on a reported basis and 20% on an organic basis.

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 09,2023

Dexcom stock rises after hours on Street-beating Q4

Dexcom shares ticked up after the market closed today on fourth-quarter results that topped the consensus forecast. Shares of DXCM rose 2.2% at $109.61 apiece after hours. The San Diego-based continuous glucose monitor (CGM) maker posted profits of $91.8 million. That amounts to 22¢ per share on sales of $815.2 million for the three months ended Dec. 31, 2022.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES